Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.

Published in:

BMC Infectious Diseases, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12879-024-09642-0

By:

• Gil-Prieto, Ruth;
• Pérez, Jaime Jesus;
• Drago, Georgina;
• Kieffer, Alexia;
• Roïz, Julie;
• Kazmierska, Paulina;
• Sardesai, Aditya;
• de Boisvilliers, Solène;
• López-Belmonte, Juan Luis;
• Beuvelet, Matthieu;
• Aldean, Javier Alvarez

Publication type:

Article